CN109689027A - 甘油三酯耳用制剂及其用途 - Google Patents

甘油三酯耳用制剂及其用途 Download PDF

Info

Publication number
CN109689027A
CN109689027A CN201780053558.8A CN201780053558A CN109689027A CN 109689027 A CN109689027 A CN 109689027A CN 201780053558 A CN201780053558 A CN 201780053558A CN 109689027 A CN109689027 A CN 109689027A
Authority
CN
China
Prior art keywords
ear
weight
composition
pharmaceutical formulation
aural preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780053558.8A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·萨韦尔
张展鹏
斯科特·科尔曼
法布里斯·皮乌
齐宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otonomy Inc
Original Assignee
Otonomy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otonomy Inc filed Critical Otonomy Inc
Publication of CN109689027A publication Critical patent/CN109689027A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780053558.8A 2016-06-29 2017-06-29 甘油三酯耳用制剂及其用途 Pending CN109689027A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356300P 2016-06-29 2016-06-29
US62/356,300 2016-06-29
PCT/US2017/040055 WO2018005830A1 (en) 2016-06-29 2017-06-29 Triglyceride otic formulations and uses thereof

Publications (1)

Publication Number Publication Date
CN109689027A true CN109689027A (zh) 2019-04-26

Family

ID=60787747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053558.8A Pending CN109689027A (zh) 2016-06-29 2017-06-29 甘油三酯耳用制剂及其用途

Country Status (9)

Country Link
US (2) US10821185B2 (https=)
EP (1) EP3478269A4 (https=)
JP (2) JP7033789B2 (https=)
KR (1) KR20190024983A (https=)
CN (1) CN109689027A (https=)
AU (1) AU2017290256A1 (https=)
CA (1) CA3029281A1 (https=)
IL (1) IL263828A (https=)
WO (1) WO2018005830A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112980878A (zh) * 2021-02-04 2021-06-18 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
CN113416608A (zh) * 2021-06-29 2021-09-21 中国热带农业科学院热带作物品种资源研究所 一种抑制单增李斯特菌的益智精油的提取方法及益智精油
CN114040782A (zh) * 2019-04-30 2022-02-11 威斯康星州医药大学股份有限公司 跨鼓膜递送平台及其用途
CN115068611A (zh) * 2022-06-24 2022-09-20 天津市农业科学院 ssc-miR-374b-3p在制备抗PDCoV增殖药物中的应用
CN115644879A (zh) * 2022-11-10 2023-01-31 合肥曦合超导科技有限公司 一种实现超导磁屏蔽的脑磁图检测设备
CN116751866A (zh) * 2023-08-09 2023-09-15 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 中耳胆脂瘤的标志物及其应用
CN117398404A (zh) * 2023-12-15 2024-01-16 北京大学口腔医学院 一种miRNA-141-5p在制备用于治疗牙周炎症性疾病药物中的应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
HRP20241559T1 (hr) 2016-05-18 2025-02-14 Sound Pharmaceuticals Incorporated Ebselen za uporabu u liječenju menierove bolesti
EP4095161A1 (en) * 2017-03-15 2022-11-30 Tsinghua University Novel anti-trkb antibodies
AU2018371787A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
US11918653B2 (en) * 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
CA3087574A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
CN112020359A (zh) 2018-02-09 2020-12-01 分贝治疗公司 含有抗铂化学保护剂的高渗药物组合物
PL3817751T3 (pl) 2018-07-03 2025-09-08 Fennec Pharmaceuticals, Inc. Postacie użytkowe bezwodnego tiosiarczanu sodu
AU2019339352B2 (en) * 2018-09-12 2025-05-22 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
US20200214976A1 (en) * 2019-01-09 2020-07-09 Spiral Therapeutics, Inc. Self-gelling solutions for administration of therapeutics to the inner ear
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
US12246024B2 (en) * 2019-12-13 2025-03-11 Free State Pharma Inc Compositions and methods for controlling cerumen production
WO2021127275A1 (en) * 2019-12-17 2021-06-24 Otonony, Inc. Gsk-3 modulator otic formulations
CN115362269A (zh) * 2020-03-06 2022-11-18 雷杰纳荣制药公司 Fascin-2(FSCN2)变体及其用途
WO2022047234A1 (en) * 2020-08-28 2022-03-03 President And Fellows Of Harvard College Drug combination kits and methods of drug delivery
CN116600787A (zh) * 2020-11-19 2023-08-15 阿库西亚医疗有限责任公司 非水性凝胶组合物
WO2022126124A1 (en) * 2020-12-10 2022-06-16 Joseph Passman Radiopaque marking compositions and delivery thereof
WO2022140636A1 (en) * 2020-12-22 2022-06-30 Otonomy, Inc. Gacyclidine otic formulations and uses thereof
JP7699789B2 (ja) * 2021-04-30 2025-06-30 ソウル ナショナル ユニバーシティ ホスピタル 感音性難聴の原因特異的治療効果を予測する方法及びそのために使用される診断キット
CN118215476A (zh) * 2021-11-08 2024-06-18 三菱瓦斯化学株式会社 用于抑制或预防内耳性耳聋的含有麦角硫因的组合物
WO2024015363A1 (en) * 2022-07-11 2024-01-18 The Johns Hopkins Univeristy Compositions and formulation methods for sustained local release of antifibrotics
TR2023015006A2 (tr) * 2023-11-14 2023-12-21 T C Ankara Ueniversitesi Rektoerluegue Rbd nanoparti̇kül i̇le yüklenmi̇ş çözünen mi̇kroi̇ğneleri̇n geli̇şti̇ri̇lmesi̇ ve kullanimi

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CN101090707A (zh) * 2004-12-09 2007-12-19 拜耳医药保健股份公司 用于在耳内卫生给药的药物
WO2008039472A2 (en) * 2006-09-26 2008-04-03 Taro Pharmaceuticals North America, Inc. Stabilizing compositions for antibiotics and methods of use
CN107405302A (zh) * 2015-02-03 2017-11-28 拜洛嘉有限责任公司 用于在耳道中局部施用的组合物

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4474572A (en) 1981-09-29 1984-10-02 Syntex (U.S.A.) Inc. Implanting device and implant magazine
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4758435A (en) 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
EP0504257A4 (en) 1989-11-29 1993-03-03 Brigham And Women's Hospital (ala il-8) 77 as a leukocyte adhesion inhibitor
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5122377A (en) * 1990-11-19 1992-06-16 A.H. Robins, Company, Incorporated Oral delivery system for veterinary drugs
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ATE163230T1 (de) 1993-03-09 1998-02-15 Epic Therapeutics Inc Makromolekulare mikropartikel und verfahren zu ihrer herstellung
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
GB9505032D0 (en) 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
WO1997031008A1 (en) 1996-02-23 1997-08-28 Industrial Research Limited Enzyme detection/assay method and substrates
IL127872A0 (en) 1996-07-19 1999-10-28 Amgen Inc Analogs of cationic proteins
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
IL135258A0 (en) 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
CN101062928B (zh) 1999-04-08 2010-10-06 工业研究有限公司 3H,5H-吡咯并[3,2-d]嘧啶-4-酮衍生物的制造方法
DE60040147D1 (de) 1999-05-28 2008-10-16 Targeted Genetics Corp Methoden und zusammensetzungen zur reduktion des tumor-nekrosis-faktor-spiegels (tnf) bei tnf-assoziierten erkrankungen
SI1194425T1 (sl) 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
ATE446366T1 (de) 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU2001284564A1 (en) 2000-08-29 2002-03-13 Albert Einstein College Of Medicine Of Yeshiva University Nucleoside metabolism inhibitors
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
HUP0303696A3 (en) * 2000-09-25 2005-05-30 Bayer Healthcare Llc Tarrytown Otic microbial combinations for treatment of animals with ruptured tympanic membrane
EP1324759A4 (en) 2000-10-12 2004-05-12 Smithkline Beecham Corp NF - G (K) B INHIBITORS
WO2002030423A1 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
CA2427284A1 (en) 2000-10-26 2002-05-30 Tularik Inc. Antiinflammation agents
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
AU2002246956B2 (en) 2001-01-04 2006-11-02 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
MXPA03006817A (es) 2001-02-01 2003-11-13 Bristol Myers Squibb Co Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
ATE363473T1 (de) 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
MXPA04002667A (es) 2001-09-19 2004-06-18 Pharmacia Corp Compuestos de pirazolilo sustituido para el tratamiento de la inflacion.
DE60229975D1 (de) 2001-10-04 2009-01-02 Smithkline Beecham Corp Nf-kb-inhibitoren
CN1310937C (zh) 2001-11-21 2007-04-18 犹太大学阿尔伯特爱因斯坦医学院 Sir2产物及活性
MXPA04005427A (es) 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
CN1627944A (zh) 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
JP2003277383A (ja) 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0313255A (pt) 2002-08-08 2005-07-12 Amgen Inc Composto, composição farmacêutica, uso de um composto e métodos de fabricar um medicamento e de preparar um composto
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
ATE457308T1 (de) 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
US20040247575A1 (en) 2003-06-03 2004-12-09 Caplice Noel M. Smooth muscle progenitor cells
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
AU2004259357B2 (en) 2003-07-24 2010-02-18 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
AU2004278382B2 (en) 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
MXPA06012870A (es) 2004-05-12 2007-02-15 Aventis Pharma Inc Acido 2-{[2-(2- metilaminopirimidin -4-il)-1h- indol-5 -carbonil]amino}-3 -(fenilpiridin -2-ilamino) propionico sustancialmente puro como inhibidor de la cinasa ikb.
US8870826B2 (en) 2004-05-24 2014-10-28 Auris Medical Llc Combined otic aspirator and medication dispenser
US8498681B2 (en) 2004-10-05 2013-07-30 Tomophase Corporation Cross-sectional mapping of spectral absorbance features
US20060105967A1 (en) 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Flavone derivatives as TNFalpha inhibitors or antagonists
CA2591296A1 (en) 2004-12-09 2006-06-15 Bayer Healthcare Ag Stabilisation of glucocorticoid esters with acids
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
AR053114A1 (es) 2005-01-12 2007-04-25 Aventis Pharma Inc Sal monopotasica del acido 2-{[2-(-2-metilamino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(fenilpiridin-2-il-amino)-propionico,inhibidora de ikk-2 quinasa
JP2008527002A (ja) 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
EP1836203A2 (en) 2005-01-14 2007-09-26 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
AU2006208042A1 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
US20060221197A1 (en) 2005-03-30 2006-10-05 Jung Edward K Image transformation estimator of an imaging device
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
CN101163481A (zh) * 2005-03-04 2008-04-16 纽罗赛斯特克公司 改进的加环利定制剂
ES2331153T3 (es) 2005-03-10 2009-12-22 Pfizer Inc. Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
CA2601468A1 (en) 2005-03-14 2006-09-21 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP4521463B2 (ja) 2005-03-17 2010-08-11 ファイザー株式会社 疼痛の治療に有用なｎ−（ｎ−スルホニルアミノメチル）シクロプロパンカルボキサミド誘導体
CA2610354C (en) 2005-05-31 2011-03-29 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2007091970A1 (en) 2006-02-06 2007-08-16 Synphora Ab Novel method and compositions for treatment of tinnitus
EP2005687B1 (en) 2006-03-24 2017-06-28 LG Electronics Inc. A method and structure of configuring preamble to support transmission of data symbol in a wireless communication system
US7744746B2 (en) 2006-03-31 2010-06-29 Exxonmobil Research And Engineering Company FCC catalyst stripper configuration
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CA2672750A1 (en) 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US9200080B2 (en) 2010-09-03 2015-12-01 Horacio Uri Saragovi Agonistic antibodies to TrkC receptors and uses thereof
US9125894B2 (en) 2010-10-06 2015-09-08 Massachusetts Eye & Ear Infirmary Methods for promoting reinnervation of auditory hair cells
EP2667881A4 (en) 2011-01-24 2015-04-22 Univ Leland Stanford Junior METHOD FOR IN VITRO GENERATION OF INTERNAL CELLS
US20140234227A1 (en) * 2011-10-10 2014-08-21 Otic Pharma Ltd. Foam formulations
DE202012100195U1 (de) 2012-01-19 2012-03-01 Nordmark Arzneimittel Gmbh & Co. Kg Neue Verwendung einer pharmazeutischen Zusammensetzung, enthaltend Ancrod
JP2015511242A (ja) 2012-02-23 2015-04-16 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） 病変性前庭障害の治療に使用するカルシニューリン阻害剤
WO2013173803A2 (en) * 2012-05-17 2013-11-21 Michael Spector Formulations of amoxicillin and clavulanate potassium and methods for using same
EP2854829A1 (en) 2012-05-30 2015-04-08 Sensorion Methods for treating vestibulotoxicity
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
EP2853533A1 (de) 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
WO2015168149A2 (en) 2014-04-28 2015-11-05 Massachusetts Eye & Ear Infirmary Sensorineural hair cell differentiation
US20170216439A1 (en) * 2014-07-29 2017-08-03 Otonomy, Inc. Otic formulations for the treatment of ceruminosis
FR3024361B1 (fr) 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
EP2982382A1 (en) 2014-08-04 2016-02-10 Sensorion Compounds for preventing ototoxicity
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2016128438A1 (en) 2015-02-11 2016-08-18 Support-Venture Gmbh Method of preventing or treating hearing loss
TWI625332B (zh) 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CN101090707A (zh) * 2004-12-09 2007-12-19 拜耳医药保健股份公司 用于在耳内卫生给药的药物
WO2008039472A2 (en) * 2006-09-26 2008-04-03 Taro Pharmaceuticals North America, Inc. Stabilizing compositions for antibiotics and methods of use
CN107405302A (zh) * 2015-02-03 2017-11-28 拜洛嘉有限责任公司 用于在耳道中局部施用的组合物

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040782A (zh) * 2019-04-30 2022-02-11 威斯康星州医药大学股份有限公司 跨鼓膜递送平台及其用途
CN112980878A (zh) * 2021-02-04 2021-06-18 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
CN112980878B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
CN113416608A (zh) * 2021-06-29 2021-09-21 中国热带农业科学院热带作物品种资源研究所 一种抑制单增李斯特菌的益智精油的提取方法及益智精油
CN115068611A (zh) * 2022-06-24 2022-09-20 天津市农业科学院 ssc-miR-374b-3p在制备抗PDCoV增殖药物中的应用
CN115644879A (zh) * 2022-11-10 2023-01-31 合肥曦合超导科技有限公司 一种实现超导磁屏蔽的脑磁图检测设备
CN115644879B (zh) * 2022-11-10 2024-08-27 合肥曦合超导科技有限公司 一种实现超导磁屏蔽的脑磁图检测设备
CN116751866A (zh) * 2023-08-09 2023-09-15 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 中耳胆脂瘤的标志物及其应用
CN116751866B (zh) * 2023-08-09 2023-10-31 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 中耳胆脂瘤的标志物及其应用
CN117398404A (zh) * 2023-12-15 2024-01-16 北京大学口腔医学院 一种miRNA-141-5p在制备用于治疗牙周炎症性疾病药物中的应用
CN117398404B (zh) * 2023-12-15 2024-03-08 北京大学口腔医学院 一种miRNA-141-5p在制备用于治疗牙周炎症性疾病药物中的应用

Also Published As

Publication number Publication date
US20200397907A1 (en) 2020-12-24
JP2022070876A (ja) 2022-05-13
KR20190024983A (ko) 2019-03-08
CA3029281A1 (en) 2018-01-04
US20180000950A1 (en) 2018-01-04
IL263828A (en) 2019-01-31
AU2017290256A1 (en) 2019-01-17
EP3478269A1 (en) 2019-05-08
US10821185B2 (en) 2020-11-03
JP2019524657A (ja) 2019-09-05
JP7033789B2 (ja) 2022-03-11
WO2018005830A1 (en) 2018-01-04
EP3478269A4 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
US20240358634A1 (en) Auris formulations for treating otic diseases and conditions
CN109689027A (zh) 甘油三酯耳用制剂及其用途
US11918653B2 (en) Triglyceride otic formulations and uses thereof
AU2018203651A1 (en) Auris formulations for treating otic diseases and conditions
TWI412370B (zh) 用於治療耳疾病及症狀的耳配方
HK40006438A (en) Triglyceride otic formulations and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006438

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190426

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40006438

Country of ref document: HK